SCHEIN BROADENING INJECTABLE GENERIC PRODUCT LINE VIA MARSAM ACQUISITION;$240 MIL. OFFER WOULD BRING ADDED CAPACITY IN PENICILLINS AND CEPHALOSPORINS
Executive Summary
Schein Pharmaceuticals is seeking to add penicillin and cephalosporin manufacturing capacity to its broad generic injectables line through a $240 mil. tender offer for Marsam Pharmaceuticals.